On May 18, 2023, Quest Diagnostics – the world’s leading provider of diagnostic information services – released new analysis that revealed the percentage of employees in the United States workforce testing positive for marijuana following an on-the-job accident increased to the highest level in 25 years in 2022, according to a news release provided by Quest Diagnostics.
In 2022, post-accident marijuana positivity of urine drug tests in the general U.S. workforce was 7.3 percent, an increase of 9 percent compared to 6.7 percent in 2021. The new peak follows a steady increase in post-accident marijuana positivity every year from 2012 to 2022. In that 10-year time frame, post-accident marijuana positivity increased by 204.2 percent.
“These increases in post-accident marijuana positivity correspond with the legalization of marijuana in certain states. In 2012, Colorado and Washington became the first states to legalize marijuana for recreational use. Since then, 19 additional states and the District of Columbia have legalized the recreational use of marijuana,” the news release from Quest Diagnostics stated.
“Intoxicating cannabis products, including marijuana, can have a major impact on safety at work and have been proven to slow reaction time, impact memory and impair skills essential to driving. State legalization of the drug creates new challenges for employers,” Katie Mueller, a senior program manager at the National Safety Council focusing on cannabis safety, explained.
In the general U.S. workforce, marijuana positivity increased 10.3 percent year over year (3.9 percent in 2021 to 4.3 percent in 2022). Marijuana positivity increased 11.8 percent (5.1 percent in 2021 to 5.7 percent in 2022) in states where recreational marijuana is legal and 8.3 percent (3.6 percent in 2021 to 3.9 percent in 2022) in states where medical marijuana is legal.
The new findings – which are from the Quest Diagnostics Drug Testing Index™ (DTI) reports that provide insights into trends in workforce drug use – will be presented by Quest Diagnostics at the 2023 National Drug and Alcohol Screening Association (NDASA) Annual Conference & Trade Show taking place from May 23, 2023, to May 25, 2023, in Bellevue, Washington.
ClearStar – a leading workforce drug and alcohol testing provider – will exhibit in Booth 114 at the 2023 NDASA Conference. ClearStar will be represented by Todd Shoulberg, President of Medical Information Services, who provides direction and leadership to ClearStar’s Medical Review Office (MRO), and Allison Crump, MRO Manager of Medical Information Services.
ClearStar is a leading global Human Resources technology company specializing in background checks, drug testing, and occupational health screening. ClearStar offers drug and alcohol testing at more than 15,000 convenient drug test locations and 3,600 rated clinics in the United States. To learn more about ClearStar, visit us at Booth 114 or contact us today.
© 2023 ClearStar. All rights reserved. – Making copies of or using any part of the ClearStar website for any purpose is prohibited unless written authorization is first obtained from ClearStar. ClearStar does not provide or offer legal services or legal advice of any kind or nature. Any information on this website is for educational purposes only.